quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·836d
PRRelease
Cartesian Therapeutics Inc. logo
Selecta Biosciences Inc. logo

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

RNAC· Cartesian Therapeutics Inc.SELB· Selecta Biosciences Inc.
Health Care
Original source

Companies

  • RNAC
    Cartesian Therapeutics Inc.
    Health Care
  • SELB
    Selecta Biosciences Inc.
    Health Care

Recent analyst ratings

  • Mar 9RNACUpdateCantor Fitzgerald$16.00
  • Jul 9RNACUpdateWedbush$38.00
  • Dec 19RNACUpdateBTIG Research$42.00
  • Aug 6RNACUpdateTD Cowen-
  • Jul 2RNACUpdateOppenheimer-
  • Jun 4RNACUpdateOppenheimer$50.00

Related

  • INSIDER17d
    SEC Form 4 filed by Hoge Elizabeth
  • INSIDER17d
    SEC Form 4 filed by Kalayoglu Murat
  • PR21d
    Cartesian Therapeutics Announces New Employment Inducement Grants
  • SEC24d
    Cartesian Therapeutics Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER41d
    Director Singer Michael gifted 6,555 units of Common Stock, decreasing direct ownership by 12% to 49,578 units (SEC Form 4)
  • ANALYST45d
    Cartesian Therapeutics upgraded by Cantor Fitzgerald with a new price target
  • SEC45d
    SEC Form 10-K filed by Cartesian Therapeutics Inc.
  • SEC45d
    Cartesian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022